Exchange: NASDAQ·Updated 08:59 AM EDT
RPRX logo

RPRXRoyalty Pharma plc - Ordinary Shares - Class A

$54.30
$0.02
(0.04%)
Pre-Market
Prev Close $54.28
EarningsAug 5
Mkt Cap$31.26B
Vol851.00
News
all
press releases
Why Is Agenus (AGEN) Down 9.6% Since Last Earnings Report?
Agenus (AGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
News Placeholder
More News
News Placeholder
GSK to Strengthen Oncology Pipeline With $10.6B Nuvalent Buyout
GSK buys Nuvalent for $10.6 billion, adding three lung cancer pipeline candidates and expanding its precision oncology presence.
Zacks
News Placeholder
Royalty Pharma (RPRX) Benefits from Biotech Funding Gap with Rising Returns and Market Dominance
Royalty Pharma (RPRX) Benefits from Biotech Funding Gap with Rising Returns and Market Dominance...
Yahoo! Finance: News
News Placeholder
Royalty Pharma Q1 Profit, Revenue Increase; Raises Full-year Portfolio Receipts Outlook
(RTTNews) - Royalty Pharma plc (RPRX) on Thursday reported higher first-quarter earnings, supported mainly by growth in income from financial royalty assets...
Nasdaq News: Markets
News Placeholder
Royalty Pharma Q1 Earnings Call Highlights
Royalty Pharma (NASDAQ:RPRX) reported what executives described as a "strong start" to 2026, driven by double-digit growth in cash receipts, active capital deployment and a series of clinical and regulatory developments across its portfolio, according to management's remarks on the company's first-q...
MarketBeat
News Placeholder
RPRX vs. AMGN: Which Stock Is the Better Value Option?
RPRX vs. AMGN: Which Stock Is the Better Value Option?
Zacks
News Placeholder
Royalty Pharma Reports Q1 2026 Results: Full Earnings Call Transcript
read more...
Benzinga
News Placeholder
Royalty Pharma PLC (RPRX) Hit a 52 Week High, Can the Run Continue?
Royalty Pharma (RPRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks
News Placeholder
Royalty Pharma (RPRX) Q1 Earnings and Revenues Surpass Estimates
Royalty Pharma (RPRX) delivered earnings and revenue surprises of +6.56% and +3.79%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Royalty Pharma (NASDAQ:RPRX) Hits New 52-Week High - Still a Buy?
Royalty Pharma (NASDAQ:RPRX) Hits New 1-Year High - Here's What Happened...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.